MUMBAI, India, June 6 -- Intellectual Property India has published a patent application (202517047414 A) filed by Cf Pharmtech, Inc.; Ruijin Hospital, Shanghai Jiaotong University School Of Medicine; and Cf Pharmtech Guangzhou Limited, Jiangsu, China, on May 16, for 'use of (-)-epigallocatechin gallate compound.'
Inventor(s) include Qu, Jieming; Zhao, Jingya; Xu, Lin; Che, Lin; Li, Xiujuan; Quan, Mengxue; and Liang, Bill Wenqing.
The application for the patent was published on June 6, under issue no. 23/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to the field of chemical pharmaceuticals and provides use of an (-)-epigallocatechin gallate (EGCG) compound. The present invention particularly relates to use of an EGCG compound in the preparation of an inhalation drug for preventing and/or treating pulmonary fibrosis diseases, an inhalable pharmaceutical composition for preventing and/or treating pulmonary fibrosis diseases, and a method for preventing and/or treating pulmonary fibrosis diseases. In the use, the EGCG compound is EGCG or a pharmaceutically acceptable salt thereof, an ester thereof, a hydrate thereof, or a solvate thereof. The drug/pharmaceutical composition taking the EGCG compound as an active ingredient provided by the embodiment is used as an inhalable drug for preventing and treating pulmonary fibrosis, such that an administration dosage can be greatly reduced, a relatively wide treatment window is provided, and a relatively slight adverse reaction and a relatively low administration frequency are achieved, thereby providing a new treatment choice for a pulmonary fibrosis patient."
The patent application was internationally filed on Nov. 17, 2023, under International application No.PCT/CN2023/132299.
Disclaimer: Curated by HT Syndication.
